Mignon A
Laboratoires Pharmacia, Saint-Quentin-en-Yvelines.
Allerg Immunol (Paris). 1994 Apr;26(4):148, 151-3.
Ansatipine, the international name of which is rifabutine, is a new specialty that was licensed in February 1993 and marketed in France in June 1993. It is an antibiotic of the rifamycin family, the result of research by Farmitalia Carlo Erba and is now presented by the Laboratoire Pharmacia. Today, rifabutine is the only molecule in the world that has been shown to be efficacious in preventative treatment for infections by the Mycobacterium avium complex (MAC) and to be officially recognised as such. Rifabutine (Ansatipine) was developed for prophylaxis of infections by MAC, because of its bacteriological activity on mycobacteria and especially on the Mycobacterium avium complex, the small number of the MAC which are naturally resistant, its high degree of tissue and intracellular penetration and its long half-life that allows a single daily dose. Clinical tests on more than 1,000 patients have shown the benefit of Ansatipine in the prophylactic treatment of MAC infections: reduction by half on the frequency of surveillance, prolongation of the delay in appearance, significant improvement in general condition and quality of life of the patients. Ansatipine is now dispensed to town pharmacies, which can only ease the daily lives of patients and reinforce the co-operation between hospital teams and general practitioners who specialize in the care of AIDS.
安莎替平，国际名称为利福布汀，是1993年2月获得许可并于1993年6月在法国上市的一种新药。它是利福霉素家族的一种抗生素，由法玛西亚公司（Farmitalia Carlo Erba）研发，现由辉瑞制药公司（Laboratoire Pharmacia）推出。如今，利福布汀是世界上唯一被证明对鸟分枝杆菌复合体（MAC）感染的预防性治疗有效的分子，并因此得到官方认可。利福布汀（安莎替平）被开发用于预防MAC感染，因为它对分枝杆菌尤其是鸟分枝杆菌复合体具有细菌学活性，对少数天然耐药的MAC有效，具有高度的组织和细胞内穿透力以及较长的半衰期，允许每日单次给药。对1000多名患者的临床试验表明，安莎替平在MAC感染的预防性治疗中具有益处：监测频率减半，发病延迟延长，患者的总体状况和生活质量有显著改善。安莎替平现已在城镇药房配药，这只会方便患者的日常生活，并加强医院团队与专门治疗艾滋病的全科医生之间的合作。
